Biotechnology

What Is Whole Genome Sequencing?

Whole genome sequencing reads nearly all of a person's roughly 3 billion DNA base pairs in a single test. It finds more kinds of genetic variation than narrower tests and is increasingly used to diagnose rare diseases and to discover drug targets.

Key points

  • Whole genome sequencing (WGS) determines the order of nearly all the DNA bases in a person's genome.
  • Whole exome sequencing reads only the protein-coding portions, the exons, which make up about 1 percent of the genome.
  • WGS can detect variants that exome sequencing misses, including changes in non-coding DNA and many structural variants.
  • In the 100,000 Genomes Project pilot, WGS produced a genetic diagnosis for 25% of people with suspected rare diseases, and 35% of those with disorders likely to have a single-gene cause.
  • Large sequenced populations let researchers link genetic variants to disease at scale, one of the main ways genomics now feeds drug discovery.

Whole genome sequencing (WGS) reads almost the entire DNA sequence of an organism in one test. For a person, that means determining the order of roughly 3 billion chemical bases, both the parts that code for proteins and the much larger parts that do not. It is the most complete genetic test in routine use.

What gets sequenced

DNA is made of four chemical bases, adenine (A), thymine (T), cytosine (C), and guanine (G), which pair up to form the two strands of the double helix. Sequencing means reading the order of those bases. WGS reads them across the whole genome, rather than focusing on selected genes.

Whole genome versus whole exome versus gene panels

Test What it reads Share of genome Typical use
Gene panel A chosen set of genes linked to a condition Very small Testing for known causes of a specific condition, such as inherited cancer risk
Whole exome sequencing (WES) The exons, the protein-coding parts of all genes About 1 percent Searching for disease-causing variants in protein-coding genes
Whole genome sequencing (WGS) Nearly all of the DNA Nearly all The broadest search, including non-coding and structural variation

Exome figure: MedlinePlus Genetics.

Because most known disease-causing variants are in protein-coding regions, exome sequencing became popular as a cheaper way to find them. WGS has several advantages that have become more important as its cost has fallen:

  • Non-coding variants. It reads the regulatory regions that switch genes on and off.
  • Structural variants. It detects large deletions, duplications, and rearrangements more reliably.
  • More even coverage. It does not depend on capturing selected regions first, so coverage of coding regions can be more uniform.
  • Mitochondrial DNA. It also reads the small separate genome inside mitochondria.

How WGS works, in brief

  1. DNA is extracted from a sample, usually blood or saliva.
  2. The DNA is broken into fragments and prepared for sequencing.
  3. The fragments are read by a sequencing machine, typically using next-generation sequencing, which reads millions of fragments in parallel.
  4. Software reassembles the reads by aligning them to a reference genome.
  5. Variants are identified by comparing the person's sequence with the reference.
  6. Variants are interpreted to decide which, if any, explain a condition. This is the hardest step. See What Are Genetic Mutations?

Most of the time and expertise in WGS goes into steps 4 to 6, the analysis and interpretation, rather than the sequencing itself.

Diagnosing rare diseases

One of the clearest clinical uses of WGS is diagnosing rare diseases, many of which are genetic. The 100,000 Genomes Project, run in England's National Health Service, reported results from its rare-disease pilot in the New England Journal of Medicine in 2021:

  • Genetic diagnoses were made in 25% of probands (the affected individuals tested).
  • Diagnostic yields were 35% for disorders likely to have a single-gene cause, compared with 11% for disorders likely to have a complex cause.
  • For intellectual disability, hearing disorders, and vision disorders, yields ranged from 40% to 55%.
  • Some diagnoses depended on variants that exome sequencing would cover poorly or miss, including non-coding, structural, and mitochondrial variants.

For families who have spent years searching for an explanation, a diagnosis can end that search, guide treatment, and inform family planning, even when no treatment yet exists.

WGS and drug discovery

Sequencing large populations lets researchers link genetic variants to disease and to traits such as cholesterol levels at enormous scale. Those links are a primary source of the human genetic evidence that makes drug targets more likely to succeed. A 2024 analysis in Nature estimated that drug mechanisms with genetic support were about 2.6 times more likely to succeed in clinical development. WGS also finds rare variants with large effects, including protective variants, which are some of the most valuable clues to new targets. See What Is Genomics?

Limitations

  • Interpretation lags sequencing. Every genome contains millions of variants, and the meaning of many is unknown. Variants of uncertain significance are common.
  • Incidental findings. A genome can reveal risks unrelated to the reason for testing, which raises questions about what to report.
  • Hard-to-read regions. Highly repetitive parts of the genome remain difficult to sequence accurately with short reads. The first complete human genome sequence, published in 2022, required long-read technologies to close the gaps.
  • Data and privacy. A genome is permanent, highly personal information that also reveals information about relatives.
  • Ancestry bias. Reference databases are dominated by people of European ancestry, which makes interpretation less reliable for others.

Sources

  1. MedlinePlus Genetics (National Library of Medicine). What are whole exome sequencing and whole genome sequencing?Regulator
  2. National Human Genome Research Institute. DNA Sequencing Fact Sheet.Regulator
  3. 100,000 Genomes Project Pilot Investigators. 100,000 Genomes pilot on rare-disease diagnosis in health care: preliminary report. New England Journal of Medicine. 2021;385(20):1868–1880.Peer-reviewed
  4. Nurk S, et al. The complete sequence of a human genome. Science. 2022;376(6588):44–53.Peer-reviewed
  5. Minikel EV, Painter JL, Dong CC, Nelson MR. Refining the impact of genetic evidence on clinical success. Nature. 2024;629:624–629.Peer-reviewed

This article is for education. It is not medical advice and not investment advice. Figures are drawn from the sources above and describe historical averages, not the prospects of any particular drug. See our editorial standards and disclaimer.